|
Romania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Romania Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Romania .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Romanian pharmaceutical and healthcare industry.
Competitive intelligence, Romanian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Romanian market.
The Romania Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Romania Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Romanian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Romania to test other views – a key input for successful budgeting and strategic business planning in the Romanian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Romanian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Romania .
- Exploit The Latest Competitive Romanian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Romania .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Romania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Romania Pharmaceuticals And Healthcare Industry SWOT |
| Romania Political SWOT |
| Romania Economic SWOT |
| Romania Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits to Potential Returns |
| Risks to Potential Returns |
Chapter - Romania – Market Summary |
| Regulatory Regime |
| Intellectual Property Issues |
| IP Deficiencies |
| Corruption |
| Pricing Regime |
| Table: Romania - Proposed Distributor Margins |
| Table: Romania - Proposed Pharmacy Margins |
| Reimbursement Regime |
Chapter - Industry Developments |
| Health Status |
| Table: Top 10 Causes Of Death In Romania, 2006 |
| Table: Disease Burden In Romania, 2006 |
| HIV Burden |
| Table: HIV Prevalence In Romania |
| Healthcare Reforms |
| Healthcare Sector Funding Crisis |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Drug Expenditure And Prescription Market Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Health Expenditure Indicators, 2004-2013 |
| Macroeconomic Forecast Scenario |
| Table: Romania - Economic Activity, 2005-2013 |
| Prescription Market Forecast |
| Table: Romania – Prescription Drugs Market Forecast, 2004-2013 |
| Patented Market Forecast |
| Table: Patented Drug Market Indicators, 2004-2013 |
| Generics Market Forecast |
| Table: Generic Drug Market Indicators, 2004-2013 |
| OTC Market Forecast |
| Table: OTC Market Indicators, 2004-2013 (RONmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Pharmaceutical Export/Import Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Socio-Demographic Indicators, 2004-2013 |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Pharmaceutical Industry |
| Manufacturing |
| Table: Ownership Of Local Companies |
| Manufacturer Developments |
| Wholesale Sector |
| Retail Sector |
| Table: Pharmacies And Pharmacy Market Ratios, 2007-2012 |
| Medical Devices |
Chapter - Company Monitor |
| Foreign Companies |
| GlaxoSmithKline (Europharm) |
| Roche |
| Sanofi-Aventis |
| Novartis |
| Pfizer |
| Krka |
| Merck & Co |
| Indigenous Companies |
| Zentiva (Incorporating Sicomed) |
| Actavis Romania (Sindan) |
| Terapia-Ranbaxy |
| Antibiotice Iasi |
| Ozone Laboratories |
| LaborMed Pharma |
Chapter - Country Snapshot: Romania Demographic Data |
| Section 1: Population |
| Section 2: Education and Healthcare |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2005-2010 (US$) |
| Table: Average Annual Wages, 2006-2010 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Romania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Romania’s pharmaceutical market has experienced rapid growth over the past four years, a trend which looks set to continue over the next five, although at a lower level. Despite the global economic downturn having major effects on foreign exchange rates – resulting in a marked decline in growth for imported medicines in euro or US dollar terms – year-on-year (y-o-y) growth in local currency remained very strong in 2008, highlighting continued demand for modern, effective treatments. Over the next five years BMI forecasts that the Romanian pharmaceutical market – which includes sales of prescription and overthe- counter (OTC) drugs – will expand at a compound annual growth rate (CAGR) of 9.75% in local currency, highlighting a prevailing attractiveness for multinationals.
BMI’s Pharmaceuticals & Healthcare Business Environment Rankings for Q209 reinforce this fact, with Romania placing sixth out of a total 20 countries covered in Central and Eastern Europe (CEE). The country displays above-average scores in the pharmaceutical market and market risk sub-sectors, although it is let down by weaker country structure and country risk scores.
Early 2009 saw the creation of a draft order for a new pricing system in Romania, which is likely to have a significant impact on prescription pharmaceuticals. The new system, which would expand the number of countries in the comparative basket, still equates prices to the lowest rather than the average prices in referenced countries. Nevertheless, a positive sign for drugmakers is the enforcement of a faster approvals system. Under the new order, decisions on price approval of a product would be adopted and communicated within 90 days of receipt of the application.
Price erosion in Romania’s prescription margins, particularly in euro terms, has also raised Romania’s profile as a parallel export source. According to the Romanian Association of Drug Manufacturers (ARPIM), the number of drugs approved for parallel exports increased to by 93% to 83 in 2008.
However, OTC medicines in Romania increased in price by up to 50% over the first quarter of 2009 according to representatives of the Romanian pharmaceutical industry. Average pharmacy prices in March 2009 were reported as growing 20% against levels in December 2008.
Q109 saw President Traian Basescu call for a reform of Romania’s healthcare system. In a speech to a joint meeting of parliament, Basescu urged the government to urgently form a strategy followed by legislative framework, giving a six-month deadline for completion. He also voiced criticism over the administration of healthcare over the past two years and argued that the system was among the poorest performing in Europe, characterised by a lack of transparency in the allocation of funds as well as inefficient use of resources.
|
Romania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |